drugset / Trial / NCT05904691
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Timeline
- Start
- 2023-11-01
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCU-10-C-110 | Unknown | — | Intravitreal |